Basiliximab biobetter - Mabtech/Sorrento

Drug Profile

Basiliximab biobetter - Mabtech/Sorrento

Alternative Names: STI-003

Latest Information Update: 13 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mabtech
  • Developer Mabtech Limited
  • Class Biobetters; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Autoimmune disorders

Most Recent Events

  • 03 Aug 2015 Mabtech announces intention to submit NDA to Chinese FDA
  • 03 Aug 2015 Monoclonal antibody biobetter licensed to Sorrento Therapeutics in European Union, Japan and North America
  • 03 Aug 2015 Phase-III clinical trials in Autoimmune disorders in China before August 2015 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top